Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 13, 2025
Daily News
May 13, 2025
- US Remains Key Market for Daiichi Sankyo: CEO
May 13, 2025
- Daiichi Sankyo Pushes Global HR Revamp, Adopts Job-Based Scheme
May 13, 2025
- Shionogi Nets Record Earnings for 3rd Consecutive Year on Overseas Expansion
May 13, 2025
- LDP Project Team Proposes Review of Coverage Rules to Fuel Biosimilar Use
May 13, 2025
- Toho Launches Specialty Drug Home Delivery Service with Vyvdura
May 13, 2025
- Industry Renews Opposition to CEA Expansion at LDP Hearing
May 13, 2025
- Bayer Files Eylea 8 mg for Macular Edema following RVO in Japan
May 13, 2025
- Lusefi Filed for Pediatric Use in Japan: Taisho
May 13, 2025
- J&J Taps Chris Rieger to Lead Japan Pharma Business
May 13, 2025
- CGP Test Data for Over 100,000 Patients Now on National Database
May 13, 2025
- MHLW Panel OKs Outline of Policy Directions to Spur Clinical Trials
May 13, 2025
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…